Short answer: the seven YK11 before and after reports below are unverified accounts of 4–8 week cycles, and the muscle figures the original article gave were guesses from photos. No study has ever given YK11 to people to measure muscle, strength or fat. All the published research is in cells and rats, plus anti-doping tests. For scale, the best-studied SARMs added about 1–1.5 kg (2–3 lb) of lean mass in controlled trials lasting 3 weeks to 3 months.
4–8 weeks
cycles in the unverified reports
1–1.5 kg
lean mass added by the best-studied SARMs in controlled trials
Below: what the science can and cannot say, how to read user reports, and the reports themselves, framed as what each person said, not as measured results. Results from other compounds are in our SARMs before and after roundup.
YK11 Summary
YK11 is a synthetic steroid (a 19-norpregnane derivative) that acts as a partial agonist of the androgen receptor: in cell tests it switched the receptor on without the full shape change that testosterone or DHT cause, which is why it is often sold as a SARM (Kanno 2011). WADA lists it by name among the SARMs prohibited at all times (WADA 2026 List).
| Question | What is known | Evidence |
|---|---|---|
| Muscle growth | In mouse muscle cells, YK11 drove muscle-cell differentiation more strongly than DHT and raised follistatin, a myostatin blocker; blocking follistatin reversed the effect (Kanno 2013) | Cell study |
| Bone | Increased growth and maturation of bone-forming cells (Yatsu 2018) | Cell study |
| Brain | Five weeks in rats raised oxidative stress, inflammation and mitochondrial damage in the hippocampus and impaired memory consolidation; exercise offset only part of it (Dahleh 2023, Dahleh 2024) | Animal |
| Testosterone suppression | Never measured in people | Not established |
| Half-life | No human pharmacokinetic study; in an anti-doping elimination study no intact YK11 reached the urine, and its breakdown products were traceable for more than 48 hours (Piper 2018) | Not established |
| Human trials | None registered or published | None |
The full fact sheet is in our YK11 review. It is not in our SARMs database charts yet because there are no human data to chart.
What the studies show: realistic YK11 timelines
There is no YK11 timeline from research, because no one has studied it in humans. What we can do is put the user reports next to what controlled trials found for SARMs that have been tested:
| Compound | Dose and length | Lean mass vs placebo | Source |
|---|---|---|---|
| LGD-4033 | 1 mg/day, 21 days, young men | +1.21 kg | Basaria 2013 |
| Ostarine | 3 mg/day, 86 days, adults over 60 | +1.3 kg | Dalton 2011 |
| YK11 | Not studied | Not established | No human study |
| User reports below | 5–20 mg/day, 4–8 weeks | Not measured (the original figures were guesses from photos) | Self-reported, unverified |
How to read the reports:
- Photos are not measurements. The original version of this page put muscle numbers on these reports by judging photos; those guesses have been removed. Water, glycogen, a pump and lighting all change how big someone looks.
- Three of the seven used other compounds too (cardarine, SR9009 or MK-677), so the photos cannot be credited to YK11 alone.
- All but one ran a SERM (Clomid) after the cycle, which tells you the users themselves expected suppression. Suppression has never been measured with YK11, so how much and how long is unknown (see YK11 suppression).
- The main safety signals are from animals: brain inflammation and oxidative stress in rats. Liver effects in people have not been studied.
- Labels are unreliable. In a test of 44 products sold online as SARMs, only 52% contained a SARM at all (JAMA 2017).
YK11 Before and After Results (User Reports)
Editor’s note: these seven reports come from the original version of this article. They are unverified individual reports: who sent them, what was in the bottle, the doses and the results could not be checked, and the original photos are no longer available. The muscle and body-fat figures the original author estimated from the photos have been removed. The cycles are what each person said they took, not recommendations, and the outcomes are not typical or expected results.
Readers can send their own reports through the contact page.
Note
Most of these users followed the cycle with Clomid, expecting their natural testosterone to be suppressed. With YK11 that has never been measured, so there is no study-based PCT for it; see YK11 dosage for what is and is not known.
YK11 Results #1
This reader reported going from carrying extra fat to lean, with visible abs, over the cycle. Fat loss of that size depends mostly on diet, and the muscle figure in the original article was a guess from photos, now removed.
Reported use: YK11 alone for 8 weeks, then clomiphene (Clomid) for 4 weeks, as the person described it; not a recommendation. Not verified.
He reported headaches during the first week of Clomid and said he felt recovered after about a month; no bloodwork was reported.
YK11 Results #2
This reader reported getting much leaner and more vascular in one cycle.
Reported use: YK11 alone for 8 weeks, then clomiphene (Clomid) for 6 weeks, as the person described it; not a recommendation. Not verified.
20 mg a day is twice the dose most of these readers used; no dose of YK11 has been tested for safety.
YK11 Results #3 (+ Cardarine)
This reader reported more muscle and less body fat. The original article noted that the after photo was taken in much better lighting, which on its own makes muscles look bigger and more defined; its muscle and fat figures were guesses from photos and have been removed.
Reported use: YK11 with cardarine for 8 weeks, then clomiphene (Clomid) for 4 weeks, as the person described it; not a recommendation. Not verified.
He also used cardarine, a PPAR-delta agonist whose development was stopped after cancers in long-term animal studies; read the cardarine fact sheet.
YK11 Results #4
This reader had trained for years, took about a year off, then used YK11 and reported the biggest changes in his legs. He was rebuilding muscle he had before, which makes it hard to tell what YK11 added; the original figures were guesses from photos and have been removed.
Reported use: YK11 alone for 8 weeks, then clomiphene (Clomid) for 4 weeks, as the person described it; not a recommendation. Not verified.
He said he felt recovered within four weeks and noticed no side effects from Clomid; no bloodwork was reported.
YK11 Results #5
This older reader used the lowest dose of the seven and reported the most change around his stomach.
Reported use: YK11 alone for 8 weeks, then a lower dose of clomiphene (Clomid) for 4 weeks, as the person described it; not a recommendation. Not verified.
He reported no adverse effects; liver enzymes and hormones were not reported.
YK11 Results #6 (+ Stenabolic)
This reader ran a short YK11 cycle and reported some change around the stomach but little in the arms, shoulders and chest.
Reported use: YK11 with stenabolic (SR9009) for 4 weeks, then stenabolic alone for 4 more weeks, no PCT, as the person described it; not a recommendation. Not verified.
Whether a short, low-dose YK11 cycle suppresses testosterone is not known; he did not report bloodwork. For what is known about stenabolic, see Stenabolic dosage.
YK11 Results #7 (+ MK-677)
This reader reported the largest change of the seven, from carrying extra fat to lean and more muscular. He combined the highest YK11 dose here with MK-677, and the original article itself called the cycle reckless; its muscle and fat figures were guesses from photos and have been removed.
Reported use: YK11 with MK-677 for 8 weeks, then clomiphene (Clomid) for 6 weeks, as the person described it; not a recommendation. Not verified.
Warning
MK-677 is not a SARM and does not replace a PCT; in a case report of LGD-4033 plus MK-677, total testosterone fell 62% (Cardaci 2022).
He reported constipation while on Clomid and no other problems; no bloodwork was reported. For the human trials on ibutamoren, see the MK-677 fact sheet.
My YK11 Results
Editor’s note: this is the original author’s personal account from the earlier version of this site. It is one person’s unverified experience without bloodwork or body-composition scans, not a measured result or a recommendation, and YK11 has still not been tested in humans.
The author reported taking YK11 for 8 weeks, followed by clomiphene (Clomid) for 4 weeks.
Muscle Mass
The author estimated gaining about two pounds of muscle a week, judged by looking in the mirror rather than by a scan. That is far more than tested SARMs produced in controlled trials (about 1–1.5 kg over 3 weeks to 3 months), and YK11 itself has no human data.
Strength
The author reported a fast, large increase in strength and frequent personal records. Strength with YK11 has never been measured in a study.
Energy
The author reported feeling wired and jittery, with energy that was easier to handle in the gym than outside it.
Fat Loss
The author reported losing body fat, including around the abdomen. No measurement method was given, and fat loss with YK11 has never been studied in people.
Libido
The author reported a rise in libido from about day five that lasted for most of the cycle.
He reported a headache at the start of Clomid and some minor side effects from YK11 that went away after stopping; no bloodwork was done. The only safety data on YK11 come from rats:
What the study found: Dahleh 2023
- Population
- rats
- Duration
- five weeks
- Result
- raised oxidative stress and inflammation in the brain and impaired memory
Tips To Get The Best YK11 Results
Because YK11 has no human research, the useful advice is about what you can check:
- Bloodwork before and after: total and free testosterone, LH, FSH, a lipid panel and liver enzymes (ALT, AST, bilirubin) are the markers SARM trials and liver-injury case reports track. Our PCT and bloodwork planner lists them.
- Liver warning signs: a systematic review counted 15 case reports of drug-induced liver injury in healthy adults using SARMs (Vignali 2023); in case reports it typically showed up as jaundice and fatigue (Khan 2022). See are SARMs liver toxic.
- Stacks multiply unknowns. Check overlapping risks before combining compounds with the stack checker and read YK11 stacks.
- Quality: products sold as SARMs are often mislabeled. If you buy, use a shop that publishes third-party lab reports for each batch; our current pick and why is in the SwissChems review.
- Sport: YK11 is named on the WADA Prohibited List, and anti-doping labs have reported it in an athlete’s sample (Sobolevsky 2024).
Conclusion
The YK11 before and after results on this page are unverified individual reports of large changes in 4–8 weeks, and the original numbers were guesses from photos. They cannot be checked against research, because YK11 has never been studied in humans. What exists is cell data on muscle and bone cells, rat data showing brain inflammation and oxidative stress, and anti-doping methods to detect it.
If you compare options, start with compounds that have human data: the SARMs database shows the evidence level for each. For YK11 head-to-heads, see YK11 vs RAD-140 and YK11 vs LGD-4033.
Frequently asked questions
What results can you expect from YK11?
Unknown; never tested in humansEvidence: User reports
User reports here are unverified, their gains were judged from photos, and several used other compounds. Tested SARMs added about 1–1.5 kg of lean mass in controlled trials.
Is YK11 a SARM or a steroid?
A steroid sold as a SARMEvidence: Lab
Chemically it is a steroid (a 19-norpregnane derivative), but in cell tests it acted as a partial agonist of the androgen receptor. WADA lists it among the SARMs.
Is YK11 a myostatin inhibitor?
Only indirectly, in cellsEvidence: Lab
In mouse muscle cells YK11 raised follistatin, a myostatin blocker, and blocking follistatin canceled its effect. This has not been shown in animals' muscles or in people.
Is YK11 suppressive?
Never measuredEvidence: Limited
Because it activates the androgen receptor, suppression of natural testosterone would be expected, but there are no data on how strong or how long it is.
What is the half-life of YK11?
Not establishedEvidence: Limited
No human pharmacokinetic study exists. In an anti-doping elimination study no intact YK11 appeared in urine, and its breakdown products were traceable for more than 48 hours.
What are the side effects of YK11?
Not studied in humansEvidence: Animal
In rats, five weeks of YK11 increased oxidative stress, inflammation and mitochondrial damage in the hippocampus and impaired memory. Users report aggression and hair shedding, which are anecdotal.
Is YK11 banned in sport?
Yes, at all timesEvidence: Law
The WADA 2026 Prohibited List names YK-11 among the SARMs, and anti-doping labs have reported finding it in an athlete's sample.
Sources
- (17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester (YK11) is a partial agonist of the androgen receptor
- Selective androgen receptor modulator, YK11, regulates myogenic differentiation of C2C12 myoblasts by follistatin expression
- Selective Androgen Receptor Modulator, YK11, Up-Regulates Osteoblastic Proliferation and Differentiation in MC3T3-E1 Cells
- YK11 induces oxidative stress and mitochondrial dysfunction in hippocampus: The interplay between a selective androgen receptor modulator (SARM) and exercise
- From gains to gaps? How Selective Androgen Receptor Modulator (SARM) YK11 impact hippocampal function: In silico, in vivo, and ex vivo perspectives
- Studies on the in vivo metabolism of the SARM YK11: Identification and characterization of metabolites potentially useful for doping controls
- Detection of selective androgen receptor modulator YK-11 in a doping control sample
- The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men
- The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial
- Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet
- LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report
- Systematic Review of Safety of Selective Androgen Receptor Modulators in Healthy Adults: Implications for Recreational Users
- Selective Androgen Receptor Modulator Induced Hepatotoxicity
- WADA: The Prohibited List (2026 List, in force from 1 January 2026)